Connect with us

Hi, what are you looking for?

Economy

Gov’t panel approves clinical trials for Clover vaccine

An expert panel from the Science and Technology department has approved Chinese drug maker Clover Biopharmaceuticals’ application for clinical trials of its coronavirus vaccine, the agency said on Friday.

A separate ethics review committee and the local Food and Drug Administration must also approve the application, Jaime Montoya, executive director of the agency’s Philippine Council for Health Research and Development, told an online news briefing.

This is the second application approved by the Science and Technology department’s expert panel, aside from Sinovac Biotech Ltd.

Mr. Montoya said the clinical trials for both companies might start by late December at the earliest. Their applications have been forwarded to the local FDA for regulatory review, he added.

Mr. Montoya said three other drug makers have applied for clinical trials — Russia’s Gamaleya Research Institute of Epidemiology and Microbiology, Janssen Pharmaceutical Companies of Johnson & Johnson and AstraZeneca.

Gamaleya is still completing some documents while the panel is still reviewing responses from Janssen. AstraZeneca was the last to submit an application, he said.

Meanwhile, Misamis Oriental Rep. Juliette T. Uy said the Phividec Industrial Estate Authority can lead the local production of vaccines under license from original manufacturers.

The country would also need safe places where enough vaccines and supplies can be stored for future needs, he said.
Ms. Uy urged the Department of Trade and Industry to “find ways to manufacture the vaccines and cold containers on a massive scale, along with the production of tens of millions of syringes and other supplies needed.”

“We must anticipate vaccination of migrant workers, returning overseas Filipino workers, foreign tourists, and crews of international airlines, passenger ships, cargo ships, personnel of foreign embassies and international regional headquarters, and visiting foreign troops,” she said. — Vann Marlo M. Villegas and Kyle Aristophere T. Atienza

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

By Diego Gabriel C. Robles THE Philippine economy expanded by 7.4% in the second quarter — slower than expected — as rising inflation weighed...

Economy

By Abigail Marie P. Yraola, Researcher THE Philippines’ merchandise trade deficit hit another record in June as imports continued to outpace exports despite a...

Economy

THE National Government’s (NG) outstanding debt as a share of the gross domestic product (GDP) eased to 62.1% at the end of June. Data...

Economy

By Keisha B. Ta-asan SOURED LOANS held by Philippine banks fell for a fourth straight month in June, bringing the nonperforming loan (NPL) ratio...

Economy

Smart says third telco player’s PCC complaint meant to avoid liability By Arjay L. Balinbin, Senior Reporter GLOBE Telecom, Inc. on Tuesday said it...

Economy

DMCI Holdings, Inc. reported on Tuesday that its second-quarter consolidated net income went up by 73% to P9.03 billion from P5.23 billion, driven by...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Investing

Instagram still holds the top spot for social media in terms of building brand reputation and expanding business potential. Every day, more and more...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.